Stem Cell as Anti-Aging "Medicine"

SAN DIEGO, CA--(Marketwire - December 28, 2009) - Medistem Inc. (PINKSHEETS: [ MEDS ]). In a collaborative publication, a group of scientists theorized that a special type of stem cell circulating in the blood stream, called the "endothelial progenitor cell," may be a critical factor in maintaining a long and healthy life. This was followed up with human data demonstrating the food supplement Stem-Kine increased the numbers of these cells in circulation.

The paper, entitled "Circulating Endothelial Progenitor Cells: A New Approach to Anti-Aging Medicine?" synthesized current research in the area of age-associated deterioration of mental, cardiovascular, and sexual function. A commonality of these conditions is a decline in circulating endothelial progenitor cells and their ability to heal damage that occurs to the lining of the blood vessels.

"Numerous experiments and clinical trials have been published describing the importance of these repair cells that the body possesses to heal internal organs," stated Dr. Doru Alexandrescu from Georgetown Dermatology, a co-author of the publication. "However, to our knowledge, this is the first comprehensive blueprint in the peer-reviewed literature of how this knowledge may be applied to the question of aging."

The paper identifies possible interventions for maintaining levels of circulating endothelial cells and reversing age-associated degeneration. Of particular interest is new data demonstrating that Stem-Kine, a commercially available oral nutritional supplement, doubled the number of circulating endothelial progenitor cells in healthy volunteers after a 2-week period.

Institutional affiliations for the authors included University of Utah, Indiana University, University of California San Diego, The Bio-Communications Research Institute, The Center for Improvement of Human Functioning International, Biotheryx, The Dove Clinic for Integrative Medicine, Novomedix Inc, Medistem Inc. and Aidan Products. The paper is freely accessible at [ http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf ]

About Medistem Inc.

Medistem Inc. is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contributing Sources

Market Wire

N@N

Stem Cell as Anti-Aging "Medicine"